Immunotherapy for Multiple Myeloma: A Powerful Weapon Against Blood Cancer

Understanding Multiple Myeloma and the Role of Immunotherapy

Multiple myeloma is a type of blood cancer that affects plasma cells, a crucial component of our immune system. These abnormal plasma cells, known as myeloma cells, multiply uncontrollably in the bone marrow, crowding out healthy blood cells and weakening the body's ability to fight infections. The immune system, which normally identifies and eliminates foreign invaders, often fails to recognize these cancerous cells, allowing them to grow and spread. This makes individuals with multiple myeloma particularly vulnerable to infections and other complications.

Fortunately, advancements in medical science have introduced powerful new treatment strategies. Among the most promising is immunotherapy, a revolutionary approach that harnesses the patient's own immune system to combat cancer. Unlike traditional treatments that directly attack cancer cells, immunotherapy works by empowering the immune system to identify and destroy myeloma cells more effectively. This article delves into the various types of immunotherapies available for multiple myeloma, how they function, their benefits, and when they are typically recommended for patients in India and around the world.

What is Immunotherapy?

Immunotherapy is a form of cancer treatment that utilizes the body's immune system to fight cancer. The immune system is a complex network of cells, tissues, and organs that work together to defend the body against diseases, including cancer. However, cancer cells can sometimes evade detection by the immune system. Immunotherapy aims to overcome this evasion by enhancing the immune system's ability to recognize and attack cancer cells.

Types of Immunotherapy for Multiple Myeloma

Several types of immunotherapy are currently used or being investigated for the treatment of multiple myeloma. These include:

1. Immunomodulating Agents (IMiDs)

Immunomodulating agents are a class of drugs that modulate, or adjust, the immune system's activity. They can either stimulate or suppress the immune response. For multiple myeloma, IMiDs are primarily used to boost the immune system's anti-myeloma activity and can also directly affect myeloma cells. The main IMiDs used are:

• Lenalidomide (Revlimid): This drug is commonly used in various stages of multiple myeloma, including maintenance therapy after other treatments have put the cancer into remission. It can also be taken after a stem cell transplant.
• Pomalidomide (Pomalyst): Pomalyst is typically prescribed for patients whose multiple myeloma has relapsed (returned) or is refractory (not responding to treatment). It is also an option for individuals with high-risk myeloma or kidney issues.
• Thalidomide (Thalomid): While less commonly used today due to the availability of newer agents, thalidomide might be considered for patients with low blood cell counts who cannot tolerate other IMiDs.

These medications are usually taken orally on a daily basis and are often administered in cycles of 21 to 28 days, frequently in combination with other myeloma drugs.

2. Monoclonal Antibodies

Antibodies are proteins naturally produced by the immune system to fight infections. Monoclonal antibodies are laboratory-made versions of these proteins, specifically designed to target particular proteins found on the surface of cancer cells. By attaching to these target proteins, monoclonal antibodies help the immune system identify and destroy myeloma cells.

Key monoclonal antibodies used in multiple myeloma treatment include:

• Isatuximab (Sarclisa): This antibody targets the CD38 protein on myeloma cells. By binding to CD38, it makes it easier for the immune system to recognize and eliminate the cancer cells. Isatuximab is generally used for patients who have already undergone at least two prior treatment regimens. It is administered intravenously over 28-day cycles, typically once every week or every two weeks.
• Elotuzumab (Empliciti): Elotuzumab targets a protein called SLAMF7, which is present on myeloma cells. It works by activating natural killer (NK) cells, a type of immune cell, which then flag myeloma cells for destruction. Empliciti is also indicated for patients who have tried other therapies previously. It is given intravenously in 28-day cycles, usually weekly or bi-weekly.

3. Bispecific T-cell Engaging Antibodies

A newer and highly innovative class of immunotherapy is the bispecific antibody. These unique antibodies are designed to bind to two different targets simultaneously: one on the myeloma cell (like BCMA) and another on a type of immune cell called a T-cell (like CD3). By bridging the myeloma cell and the T-cell, these antibodies bring the immune cell directly to the cancer cell, triggering a potent anti-cancer response.

• Teclistamab (Tecvayli): This is an example of a bispecific antibody approved for multiple myeloma. It targets both CD3 on T-cells and BCMA on myeloma cells. Teclistamab is generally reserved for patients who have exhausted at least four prior treatment options. It is administered via injection just under the skin, with a specific dosing schedule that usually involves more frequent injections initially, followed by weekly administrations.

4. CAR T-cell Therapy

Chimeric Antigen Receptor (CAR) T-cell therapy is a highly personalized form of immunotherapy. In this treatment, a patient's own T-cells are collected, genetically engineered in a laboratory to produce CARs that specifically target myeloma cells (e.g., BCMA), and then infused back into the patient. These modified T-cells are now equipped to recognize and destroy myeloma cells much more effectively. CAR T-cell therapies are relatively new for multiple myeloma, and research is ongoing to understand their long-term outcomes.

5. Stem Cell Transplantation (SCT)

While not strictly immunotherapy, stem cell transplantation, particularly autologous stem cell transplantation (ASCT), is a cornerstone treatment for multiple myeloma, often used in conjunction with or following other therapies. In ASCT, a patient's own stem cells are collected, high-dose chemotherapy is administered to eliminate cancer cells, and then the collected stem cells are returned to the patient to help rebuild the bone marrow and immune system. In some cases, a doctor might recommend a tandem transplant, which involves two ASCT procedures spaced 6 to 12 months apart.

How Immunotherapy Works Against Multiple Myeloma

Immunotherapies work through several mechanisms to combat multiple myeloma:

• Enhancing Immune Recognition: Monoclonal antibodies and bispecific antibodies help the immune system 'see' myeloma cells by marking them or bringing immune cells closer.
• Directly Affecting Myeloma Cells: Some immunotherapies, like IMiDs, can directly induce death in myeloma cells or inhibit their growth.
• Boosting Immune Cell Activity: CAR T-cell therapy and some antibodies activate and multiply immune cells like T-cells and NK cells, turning them into potent cancer fighters.
• Stripping Camouflage: Immunotherapies can strip myeloma cells of their ability to hide from the immune system and prevent the cancer from further weakening the body's defenses.

Diagnosis and Treatment Decisions

The diagnosis of multiple myeloma typically involves blood tests, urine tests, bone marrow biopsy, and imaging studies (like X-rays, CT scans, or PET scans) to assess the extent of the disease. Once diagnosed, treatment decisions are highly individualized and depend on factors such as the stage of the cancer, the patient's overall health, age, and the presence of any other medical conditions.

Immunotherapy is often integrated into treatment plans, especially for patients with relapsed or refractory disease, or as part of initial therapy for newly diagnosed individuals. The choice of specific immunotherapy, its combination with other drugs, and the treatment schedule are determined by the treating hematologist-oncologist.

Potential Side Effects and Management

Like all cancer treatments, immunotherapies can have side effects. The specific side effects vary depending on the type of immunotherapy used. Common side effects may include:

• Fatigue
• Flu-like symptoms (fever, chills, body aches)
• Skin rash
• Nausea and vomiting
• Diarrhea
• Lowered blood cell counts (increasing risk of infection, anemia, or bleeding)
• Infusion-related reactions (for IV therapies)

It is crucial for patients to discuss potential side effects with their doctor. Many side effects can be managed effectively with supportive care, medications, or dose adjustments. Regular monitoring through blood tests and check-ups is essential throughout the treatment period.

When to Consult a Doctor

If you experience any of the following symptoms, it is important to consult a doctor promptly:

• Unexplained fatigue or weakness
• Bone pain, especially in the back, ribs, or hips
• Frequent infections or fevers
• Unexplained bruising or bleeding
• Unexplained weight loss
• Numbness or tingling in the hands or feet

If you have been diagnosed with multiple myeloma, regular follow-up with your oncologist is essential to monitor your condition and adjust treatment as needed. Do not hesitate to report any new or worsening symptoms to your healthcare team.

The Future of Immunotherapy in Multiple Myeloma

The field of immunotherapy for multiple myeloma is rapidly evolving. Researchers are continuously developing new therapies and refining existing ones to improve efficacy and reduce side effects. The approval of new immunotherapies, including CAR T-cell therapies and bispecific antibodies since 2021, signifies a significant leap forward. While long-term data is still being gathered for these newer treatments, they offer renewed hope and expanded options for patients facing this challenging blood cancer. The ongoing research promises even more targeted and effective treatments in the years to come, aiming to improve outcomes and quality of life for individuals with multiple myeloma.